Stem Cells

Yoshimoto, Momoko; Koenig, Joyce M.

doi:10.1016/j.clp.2015.04.008

Cited by 5 publications

(2 citation statements)

References 121 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The potential neuroprotective efficacy of stem cell treatments appears to be mediated by multiple protective effects including promotion of proliferation, growth and differentiation through release of trophic factors and chemokines to support host cell survival and development, and their ability to modulate the inflammatory responses post-HI [ 175 , 176 , 177 ]. A variety of different stem cells are currently being assessed clinically and preclinically, including human amniotic epithelial cells (hAECs) [ 174 , 177 , 178 ] and umbilical cord blood (UCB).…”

Section: Potential Neuroprotective Treatments Showing Promise In Pmentioning

confidence: 99%

Preventing Brain Injury in the Preterm Infant—Current Controversies and Potential Therapies

Yates

Gunn

Bennet

et al. 2021

IJMS

View full text Add to dashboard Cite

Preterm birth is associated with a high risk of morbidity and mortality including brain damage and cerebral palsy. The development of brain injury in the preterm infant may be influenced by many factors including perinatal asphyxia, infection/inflammation, chronic hypoxia and exposure to treatments such as mechanical ventilation and corticosteroids. There are currently very limited treatment options available. In clinical trials, magnesium sulfate has been associated with a small, significant reduction in the risk of cerebral palsy and gross motor dysfunction in early childhood but no effect on the combined outcome of death or disability, and longer-term follow up to date has not shown improved neurological outcomes in school-age children. Recombinant erythropoietin has shown neuroprotective potential in preclinical studies but two large randomized trials, in extremely preterm infants, of treatment started within 24 or 48 h of birth showed no effect on the risk of severe neurodevelopmental impairment or death at 2 years of age. Preclinical studies have highlighted a number of promising neuroprotective treatments, such as therapeutic hypothermia, melatonin, human amnion epithelial cells, umbilical cord blood and vitamin D supplementation, which may be useful at reducing brain damage in preterm infants. Moreover, refinements of clinical care of preterm infants have the potential to influence later neurological outcomes, including the administration of antenatal and postnatal corticosteroids and more accurate identification and targeted treatment of seizures.

show abstract

Section: Potential Neuroprotective Treatments Showing Promise In Pmentioning

confidence: 99%

Preventing Brain Injury in the Preterm Infant—Current Controversies and Potential Therapies

Yates

Gunn

Bennet

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Therapeutic efficacy of various stem cells including embryonic stem cells, inducible pluripotent stem cells, endothelial progenitor cells, neural stem cells and MSC for neonatal brain disorders have been extensively discussed in the literature [30,31,32,33]. However, it is very difficult to choose among the various types and sources of stem cells and to identify those that ultimately exhibit the best therapeutic efficacy in protecting against neonatal brain injuries.…”

Section: Determining the Optimal Cell Type For Stem Cell Transplantationmentioning

confidence: 99%

Stem Cells for Neonatal Brain Disorders

2016

View full text Add to dashboard Cite

Despite recent advances in neonatal intensive care medicine, neonatal brain injury resulting from intraventricular hemorrhage or hypoxic-ischemic encephalopathy remains a major cause of neonatal mortality and neurologic morbidities in survivors. Several studies have indicated that stem cell therapy is a promising novel therapy for neonatal brain injury resulting from these disorders. This review summarizes recent advances in stem cell research for treating neonatal brain injury due to intraventricular hemorrhage or hypoxic-ischemic encephalopathy with a particular focus on preclinical data, covering important issues for clinical translation such as optimal cell type, route, dose and timing of stem cell therapy, and translation of these preclinical results into a clinical trial.

show abstract

Window of opportunity for human amnion epithelial stem cells to attenuate astrogliosis after umbilical cord occlusion in preterm fetal sheep

Davidson

Heuij

Fraser

et al. 2020

Stem Cells Translational Medicine

View full text Add to dashboard Cite

There is increasing evidence that administration of many types of stem cell, including human amnion epithelial cells (hAECs), can reduce hypoxic-ischemic injury, including in the perinatal brain. However, the therapeutic window for single dose treatment is not known. We compared the effects of early and delayed intracerebroventricular administration of hAECs in fetal sheep at 0.7 gestation on brain injury induced by 25 minutes of complete umbilical cord occlusion (UCO) or sham occlusion. Fetuses received either 1 × 10 6 hAECs or vehicle alone, as an infusion over 1 hour, either 2 or 24 hours after UCO. Fetuses were killed for brain histology at 7 days post-UCO. hAEC infusion at both 2 and 24 hours had dramatic anti-inflammatory and anti-gliotic effects, including significantly attenuating the increase in microglia after UCO in the white and gray matter and the number of astrocytes in the white matter. Both protocols partially improved myelination, but had no effect on total or immature/mature numbers of oligodendrocytes. Neuronal survival in the hippocampus was increased by hAEC infusion at either 2 or 24 hours, whereas only hAECs at 24 hours were associated with improved neuronal survival in the striatum and thalamus. Neither protocol improved recovery of electroencephalographic (EEG) power. These data suggest that a single infusion of hAECs is antiinflammatory, anti-gliotic, and neuroprotective in preterm fetal sheep when given up to 24 hours after hypoxia-ischemia, but was associated with limited white matter protection after 7 days recovery and no improvement in the recovery of EEG power.

show abstract

Stem Cells

Cited by 5 publications

References 121 publications

Preventing Brain Injury in the Preterm Infant—Current Controversies and Potential Therapies

Preventing Brain Injury in the Preterm Infant—Current Controversies and Potential Therapies

Stem Cells for Neonatal Brain Disorders

Window of opportunity for human amnion epithelial stem cells to attenuate astrogliosis after umbilical cord occlusion in preterm fetal sheep

Contact Info

Product

Resources

About